PRAX

Praxis Precision Medicines Inc

256.47

Oct 21 • 3:59 PM ET -8.02 (-3.03%)

257.70

Aftermarket • 7:30 PM ET +1.23 (0.48%)

Healthcare Biotechnology USA Mid NASD

Peers: XENE RAPP JAZZ STOK AXSM NBIX BHVN ACAD SUPN BIIB

| Held by: VTI VB IWM XBI VBR VXF IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT
Market Cap	7.16B
Enterprise Value	6.40B
Income	-339.13M
Sales	0.00M
Book/sh	48.04
Cash/sh	27.17
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	168
IPO	Oct 16, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.34
P/C	9.44
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	15.73
Current Ratio	15.73
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-12.94
EPS next Y	-10.03
EPS next Q	-3.54
EPS this Y	-1.74%
EPS next Y	26.84%
EPS next 5Y	-
EPS past 3/5Y	42.16% 13.34%
Sales past 3/5Y	- -
EPS Y/Y TTM	-5.32%
Sales Y/Y TTM	-100.00%
EPS Q/Q	13.23%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	21.76% -

Insider Own	5.95%
Insider Trans	-0.69%
Inst Own	116.87%
Inst Trans	7.89%
ROA	-36.80%
ROE	-38.86%
ROIC	-25.29%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-4.53%
SMA50	-18.72%
SMA200	-18.66%
Trades

Shs Outstand	27.92M
Shs Float	26.26M
Short Float	15.95%
Short Ratio	9.28
Short Interest	4.19M
52W High	392.70 -34.69%
52W Low	154.45 66.05%
Volatility	5.74% 5.16%
ATR (14)	14.33
RSI (14)	38.96
Beta	2.87
Rel Volume	1.10
Avg Volume	451.42K
Volume	497,056

Perf Week	7.30%
Perf Month	-14.69%
Perf Quarter	-20.45%
Perf Half Y	-23.96%
Perf YTD	-12.98%
Perf Year	34.97%
Perf 3Y	1324.83%
Perf 5Y	-21.28%
Perf 10Y	-
Recom	1.33
Target Price	650.00
Prev Close	264.49
Price	256.47
Change %	-3.03%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-26	Initiated	JP Morgan	Overweight	$700
Oct-15-26	Initiated	UBS	Buy	$706
Jul-13-26	Initiated	Goldman	Buy	$447
Jun-18-26	Initiated	RBC Capital Mkts	Outperform	$449
Apr-10-26	Initiated	Raymond James	Strong Buy	$815
Feb-24-26	Initiated	Wolfe Research	Outperform	$500
Feb-02-26	Initiated	Wells Fargo	Equal Weight	$282
Dec-15-25	Reiterated	Oppenheimer	Outperform	$250 → $750
Nov-19-25	Initiated	BTIG Research	Buy	$424
Jun-02-25	Resumed	Oppenheimer	Outperform	$97
May-07-25	Initiated	Chardan Capital Markets	Buy	$80
Mar-03-25	Reiterated	H.C. Wainwright	Buy	$120 → $105
Feb-11-25	Initiated	Deutsche Bank	Buy	$111
Aug-05-24	Initiated	Oppenheimer	Outperform	$134
Jun-24-24	Initiated	Needham	Buy	$145
Jun-18-24	Initiated	Guggenheim	Buy	$155
May-01-24	Initiated	Robert W. Baird	Outperform	$117
Sep-19-23	Initiated	Truist	Buy	$10
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral	$4
Dec-16-21	Initiated	H.C. Wainwright	Buy	$48

Show Previous Ratings

Oct-16-26 09:38AM	Workday downgraded, Fox Corp. upgraded: Wall Street's top analyst calls (The Fly)
Oct-02-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-26 08:30AM	Praxis Precision Medicines, Inc. Q2 2026 Earnings Call Summary (Moby)
Aug-06-26 07:15PM	Praxis Precision Medicines Inc (PRAX) (Q2 2026) Earnings Call Highlights: FDA Approvals on ... (GuruFocus.com) +15.95%
01:49PM	Loading…
01:49PM	These Two Stocks Hit Fresh 52-Week Highs Today DCTH Clocks Best Day In Nearly 15 Months (Stocktwits)
08:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Aug-04-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-30-26 04:01PM	Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 (GlobeNewswire) +5.75%
Jul-07-26 08:00AM	Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor (GlobeNewswire)
Jul-02-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-29-26 04:30PM	Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies (GlobeNewswire) +6.95%
Jun-22-26 08:47AM	Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy Designation (InvestorsHub) +7.47%
08:00AM	Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants (GlobeNewswire)
Jun-04-26 04:01PM	Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference (GlobeNewswire) -5.08%
07:15AM	Loading…
Jun-03-26 07:15AM	NewLimits $435M megaround; Lillys busy dealmaking week (BioPharma Dive) +8.08%
Jun-02-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -23.00%
10:13AM	The Shocking Twist That Sent This Seizure-Focused Biotech Into A Dive (Investor's Business Daily)
Jun-01-26 07:52PM	PRAX Stock Drops 12% After Hours On Trial Setback Retail Eyes FDA Approval Of Other Pipeline Candidates (Stocktwits)
04:15PM	Praxis Precision Medicines Provides Vormatrigine Program Update (GlobeNewswire)
May-08-26 08:30AM	Praxis Precision Medicines, Inc. Q1 2026 Earnings Call Summary (Moby)
May-07-26 08:00AM	Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-05-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-04-26 04:01PM	Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference (GlobeNewswire)
Apr-14-26 11:17AM	Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish Breakout (Investor's Business Daily) +8.39%
07:30AM	Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor (GlobeNewswire)
Apr-13-26 08:00AM	Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 (GlobeNewswire)
Apr-06-26 08:00AM	Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy (GlobeNewswire)
Apr-02-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-30-26 04:01PM	Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs (GlobeNewswire) +16.55%
09:26AM	Loading…
Mar-09-26 09:26AM	Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures (Benzinga)
Mar-04-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-26 08:08PM	Praxis Precision Medicines, Inc. Q4 2025 Earnings Call Summary (Moby)
02:01PM	Praxis Precision Medicines Inc (PRAX) Q4 2025 Earnings Call Highlights: Strong Financial ... (GuruFocus.com)
12:27PM	Praxis Precision Medicines Q4 Earnings Call Highlights (MarketBeat)
07:30AM	Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
03:43AM	Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide (Insider Monkey)
Feb-18-26 07:40PM	Wells Fargo Cautious on Praxis Precision (PRAX) After Recent Revenue Estimates (Insider Monkey)
07:20AM	Praxis Precision Medicines Inc (PRAX) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-16-26 12:23PM	Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX) (Insider Monkey)
Feb-14-26 08:02PM	Praxis Precision Medicines Eyes Mid-February Dual NDA Filings, Maps ET Launch and Epilepsy Pipeline (MarketBeat)
Feb-13-26 09:53AM	Guggenheim Raises Target on Praxis Precision Medicines (PRAX) to $800 (Insider Monkey)
Feb-09-26 04:01PM	Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-04-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-26 06:40AM	SEQSTER and Praxis expand collaboration to expedite CNS disorder trials (Clinical Trials Arena)
Feb-02-26 09:47AM	Palantir upgraded, Best Buy downgraded: Wall Street's top analyst calls (The Fly)
Jan-15-26 11:35AM	Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus (Insider Monkey)
Jan-13-26 04:30PM	Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy (GlobeNewswire) +6.28%
Jan-12-26 08:00AM	Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress (GlobeNewswire)
Jan-11-26 01:07AM	Needham Analyst Keeps a Buy Rating on Praxis Precision Medicines, Inc. (PRAX) (Insider Monkey)
Jan-09-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-26 04:45PM	Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments (GlobeNewswire)
Jan-06-26 11:15PM	Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering (GlobeNewswire) +7.23%
04:03PM	Praxis Precision Medicines, Inc. Announces Proposed Public Offering (GlobeNewswire)
Dec-30-25 08:05AM	Praxis Precision granted Breakthrough Therapy designation for Ulixacaltamide (TipRanks)
Dec-29-25 07:39PM	Why Praxis Precision Medicines Stock Popped Today (Motley Fool) +13.25%
04:32PM	Stocks Settle Lower as Weakness in Big Tech Weighs (Barchart)
10:02AM	Stocks Slip Due to Weakness in Megacap Technology Stocks (Barchart)
08:00AM	Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor (GlobeNewswire)
07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.)
Dec-12-25 05:18AM	Praxis tees up another approval filing; Geron turns to layoffs (BioPharma Dive)
Dec-11-25 08:00AM	Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 (GlobeNewswire)
07:44AM	TD Cowen Lifts Praxis Precision Medicines Inc. (PRAX) Price Target amid NDA for Essential Tremor Treatment (Insider Monkey)
Dec-09-25 04:01PM	Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy (GlobeNewswire)
12:20AM	Praxis Precision Medicines Inc. (PRAX) Secures Analyst Confidence After Key FDA and Trial Wins (Insider Monkey)
Dec-08-25 10:39AM	PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know (Zacks) +9.27%
08:00AM	Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies (GlobeNewswire)
Dec-05-25 04:58PM	Health Care Roundup: Market Talk (The Wall Street Journal) +30.54%
04:15PM	Praxis Surges 31%, Hitting Another 3-Year High, On A Surprise Win In Epilepsy (Investor's Business Daily)
12:34PM	Stock Market Today: S&P 500 and Nasdaq Gain For Fourth Straight Day Ahead of Highly-Anticipated Fed Policy Meeting (TheStreet)
12:34PM	Stock Market Today: Nasdaq, Dow Gain As Consumer Sentiment Rises for First Time in Five Months (TheStreet)
05:00AM	Praxis soars higher; Bristol Myers CAR-T therapy wins broader use (BioPharma Dive)
Dec-04-25 04:10PM	Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (GlobeNewswire)
04:01PM	Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor (GlobeNewswire)
Dec-03-25 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-25 04:01PM	Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting (GlobeNewswire) +12.40%
Nov-20-25 04:01PM	Praxis Precision Medicines to Participate in Upcoming Fireside Chat (GlobeNewswire) -13.33%
Nov-19-25 09:07AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: DoorDash, Freeport-McMoRan, GitLab, Home Depot, Medtronic, Molson-Coors, and More (24/7 Wall St.)
Nov-06-25 08:00AM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-05-25 04:01PM	Praxis Precision Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 08:00AM	Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback (GlobeNewswire) -5.63%
Nov-03-25 11:15AM	Oppenheimer Lifts Price Target for Praxis Medicines (PRAX), Keeps Outperform Rating (Insider Monkey) -8.44%
Oct-29-25 10:00AM	Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-26-25 03:47AM	Meet the Biotech Stock That Just Jumped 251% Higher (Motley Fool)
Oct-22-25 07:41AM	Praxis Precision Medicines Reports Positive Phase 3 Results for Ulixacaltamide in Essential Tremor (Insider Monkey)
Oct-17-25 10:09AM	Praxis Precision (PRAX) Triples on Stellar Drug Trial Results (Insider Monkey) +16.77%
09:10AM	Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains? (Zacks)
08:49AM	Tesla, Nvidia, Rigetti, Praxis: Trending Stocks (Yahoo Finance Video)
Oct-16-25 11:45PM	Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering (GlobeNewswire) +183.71%
04:01PM	Praxis Precision Medicines, Inc. Announces Proposed Public Offering (GlobeNewswire)
03:49PM	Praxis Precision surges, analysts see blockbuster potential for ulixacaltamide (Investing.com)
02:14PM	Praxis Precision's tremor-drug trial has succeeded where others have failed. The stock is skyrocketing. (MarketWatch)
12:07PM	A Treatment for Tremors Is Back From the Dead. This Stock Is Up 200%. (Barrons.com)
11:53AM	The 'Groundbreaking' Results That Sent Praxis Precision Medicines Up 200% (Investor's Business Daily)
11:35AM	This Strong Buy Stock Has More Than Tripled Today. Should You Buy It Here? (Barchart)
08:21AM	A longshot bet on a tremor drug pays off (BioPharma Dive)
07:00AM	Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor (GlobeNewswire)
Oct-02-25 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-29-25 07:00AM	ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DeSimone Jill	Director	Jun 24 '26	Option Exercise	71.20	11,600	825,954	13,937	Jun 26 05:09 PM
DeSimone Jill	Director	Jun 24 '26	Sale	311.32	11,600	3,611,335	2,337	Jun 26 05:09 PM
DeSimone Jill	Director	Jun 24 '26	Proposed Sale	311.32	11,600	3,611,336		Jun 24 04:18 PM
Nemiroff Alex	General Counsel and Secretary	Nov 20 '25	Option Exercise	73.76	25,130	1,853,531	45,962	Nov 21 09:41 PM
Nemiroff Alex	General Counsel and Secretary	Nov 20 '25	Sale	193.09	25,130	4,852,256	20,832	Nov 21 09:41 PM
Mastrocola Lauren	Principal Accounting Officer	Nov 20 '25	Option Exercise	61.12	13,600	831,257	24,042	Nov 21 09:39 PM
Mastrocola Lauren	Principal Accounting Officer	Nov 20 '25	Sale	192.08	13,600	2,612,244	10,442	Nov 21 09:39 PM
Nemiroff Alex	Officer	Nov 20 '25	Proposed Sale	193.09	25,130	4,852,249		Nov 20 11:34 AM
Mastrocola Lauren	Officer	Nov 20 '25	Proposed Sale	192.08	13,600	2,612,239		Nov 20 11:25 AM

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

PresidentMr. Marcio Silva De'Souza M.B.A.

CFO & TreasurerMr. Timothy Edwin Kelly

General Counsel & SecretaryMr. Alex Nemiroff J.D.

Ph.D.Dr. Steven Petrou B.Sc. (Hons.)

Chief Operating OfficerMs. Megan T. Sniecinski

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRAX

Praxis Precision Medicines Inc

Upgrade your Finviz experience